[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Al-Barrag A, Al-Shaer M, Al-Matary N, Al-Hamdani M: 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea. Clin Ophthalmol; 2010;4:801-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea.
  • OBJECTIVE: To evaluate the efficacy and risks of complications of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of corneal intraepithelial neoplasia (CIN), and conjunctival squamous cell carcinoma (SCC).
  • PARTICIPANTS: Fifteen patients with histological evidence CIN or SCC of the conjunctiva and cornea were identified by tumor biopsy.
  • METHODS: All patients clinically evident of CIN, or SCC were evaluated, with maximum 30 months of follow-up were treated with pulsed dosing of 1% 5-FU.
  • Treatment cycles were defined as four times per day for 4 days using the medication followed by 30 days without medication.
  • The number of initial treatment was six cycles.
  • Excision biopsy proved seven cases as CIN, and eight cases as locally invasive SCC.
  • Additional chemotherapy was given after the initial treatment cycles, only for one case.
  • CONCLUSIONS: Adjuvant 1% topical 5-FU appears to be effective in the prevention of recurrence of conjunctival or corneal CIN and SCC after excision biopsy.
  • It is well-tolerated and an effective method of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 2009 Aug;28(7):821-4 [19574900.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1747-54 [15350332.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Doc Ophthalmol. 1986 Dec 30;64(1):31-42 [3582100.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3 [3980172.001]
  • [Cites] Am J Ophthalmol. 1984 May;97(5):547-59 [6720832.001]
  • [Cites] Am J Ophthalmol. 1983 Mar;95(3):359-63 [6829682.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1338-44 [9097771.001]
  • [Cites] Arch Ophthalmol. 1997 Jun;115(6):808-15 [9194740.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1600-1 [9400803.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Ophthalmologica. 1979;178(4):198-203 [481865.001]
  • [Cites] Am J Ophthalmol. 1976 Feb;81(2):198-206 [766640.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):381-3 [9439364.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Cornea. 1999 Jan;18(1):59-62 [9894938.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Arch Ophthalmol. 1999 Apr;117(4):544-5 [10206591.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2190-5 [11097594.001]
  • [Cites] Ophthalmol Clin North Am. 2005 Mar;18(1):1-13, vii [15763187.001]
  • [Cites] Ophthalmology. 2002 Feb;109(2):249-52 [11825803.001]
  • (PMID = 20689797.001).
  • [ISSN] 1177-5483
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2915867
  • [Keywords] NOTNLM ; chemotherapy / fluorouracil / neoplasia / treatment cycles
  •  go-up   go-down


2. Huerva V, Mangues I: Treatment of conjunctival squamous neoplasias with interferon alpha 2ab. J Fr Ophtalmol; 2008 Mar;31(3):317-25
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival squamous neoplasias with interferon alpha 2ab.
  • The classical approach to the treatment of squamous neoplasias of the ocular surface is based on surgical resection and cryotherapy.
  • Primary or adjuvant chemotherapy with mitomycin C (MMC) or 5-fluorouracil has been employed to treat these neoplasias, but severe side effects on the ocular surface have been described.
  • The experience in the treatment of conjunctiva-cornea intraepithelial neoplasia (CIN) with topical or intralesional INF alpha 2b is based on isolated cases or very short series.
  • The safety and effectiveness of INF alpha 2b in the treatment of primary and recurrent cases of CIN are described.
  • The absence of serious side effects after topical administration of INF alpha 2b leads to the recommendation of this modality of therapy for primary and recurrent cases of CIN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Fluorouracil / therapeutic use. Humans. Mitomycin / therapeutic use. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404128.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Lyall DA, Srinivasan S, Roberts F: Limbal stem cell failure secondary to advanced conjunctival squamous cell carcinoma: a clinicopathological case report. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limbal stem cell failure secondary to advanced conjunctival squamous cell carcinoma: a clinicopathological case report.
  • A 67-year-old man with a history of multiple myeloma (treated with chemotherapy) was referred with a left hyperaemic conjunctival lesion covering almost 360° of the limbus and extending onto the corneal surface.
  • Conjunctival biopsy revealed conjunctival intraepithelial neoplasia.
  • Initial treatment consisted of topical and intralesional injections of interferon α-2b.
  • The patient subsequently developed limbal stem cell deficiency resulting in a persistent non-healing corneal epithelial defect.
  • Histopathology revealed a conjunctival squamous cell carcinoma.
  • This case highlights a rare case of advanced ocular surface neoplasia causing secondary limbal stem cell deficiency.
  • Medical and surgical management of ocular surface neoplasia with limbal stem cell transplantation is effective in treating such cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22121391.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027379
  •  go-up   go-down


Advertisement
4. Yeatts RP, Engelbrecht NE, Curry CD, Ford JG, Walter KA: 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology; 2000 Dec;107(12):2190-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea.
  • OBJECTIVE: To evaluate the efficacy of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of conjunctival and corneal intraepithelial neoplasia.
  • PARTICIPANTS: Seven patients with histologic evidence of intraepithelial neoplasia were identified by conjunctival biopsy or tumor excision.
  • Topical 1% 5-FU was administered four times daily for 2 to 4 days for each cycle.
  • The number of initial treatment cycles was two to six, with the time between cycles being 30 to 45 days.
  • MAIN OUTCOME MEASURES: The presence or absence of clinically evident intraepithelial neoplasia was evaluated after each treatment interval.
  • RESULTS: Four patients remain disease free with a mean follow-up of 18.5 months (range, 7-36 months) with no additional treatment after the initial treatment cycles (mean, 3.75 cycles; range, 2-5 cycles).
  • Three patients had recurrence of disease after the initial treatment cycles.
  • Two patients were treated with additional cycles for recurrent disease (six cycles in one patient and five cycles in the other patient) and are free of disease at 20 and 21 months after treatment, respectively.
  • One patient had persistent disease despite treatment with topical 5-FU and was treated with topical mitomycin C with resolution of the disease without recurrence for 16.5 months.
  • No adverse reactions to pulse dose treatment with topical 5-FU were noted.
  • CONCLUSIONS: Pulsed dosing with 1% topical 5-FU for the treatment of conjunctival and corneal intraepithelial neoplasia, alone or as an adjunct to excision of bulky disease, is a well-tolerated and effective method of treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Fluorouracil / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Male. Ophthalmic Solutions / therapeutic use. Prospective Studies

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11097594.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Ophthalmic Solutions; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Kobayashi A, Yoshita T, Uchiyama K, Shirao Y, Kitagawa K, Fujisawa A, Tseng SC: Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b. Jpn J Ophthalmol; 2002 Mar-Apr;46(2):215-7
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b.
  • BACKGROUND: Interferon alpha-2b (IFN alpha 2b) was recently shown to be effective as an alternative therapy for conjunctival intraepithelial neoplasia (CIN).
  • Herein, we report our successful management of CIN by the use of IFN alpha 2b.
  • Slit-lamp microscope examination revealed a tumorous lesion involving the bulbar and palpebral conjunctiva as well as the limbus, from the 3-o'clock position to the 8-o'clock position.
  • She had already undergone cryotherapy in the same eye in another hospital, twice for a lesion on the lower tarsal conjunctiva and once for a lesion on the upper tarsal conjunctiva.
  • The histological diagnosis had been CIN.
  • Two weeks after the initial treatment, the tumorous lesion disappeared.
  • CONCLUSION: Topical and subconjunctival IFN alpha 2b is a valuable treatment option for CIN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12062230.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


6. Zaki AA, Farid SF: Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up. Cornea; 2009 Oct;28(9):986-8
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
  • PURPOSE: The aim of this work is to report the long-term results of using immunotherapy for the management of cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma after surgical excision of the neoplasm.
  • METHODS: Ten eyes of 10 patients with cornea and conjunctiva intraepithelial neoplasia or squamous cell carcinoma had wide surgical excisions of the neoplasm after evaluation of the level of corneal involvement using ultrasound biomicroscopy.
  • All eyes received topical cyclosporine A (0.05%) and topical mitomycin C (0.01%) 4 times daily for 12 weeks after surgery.
  • Epithelial toxicity (punctate keratopathy) occurred in 3 eyes, ocular irritation and mild conjunctival hyperemia in 5 eyes, and lid toxicity in 2 cases during the treatment with mitomycin C.
  • There were no serious complications that necessitated stopping the treatment.
  • CONCLUSION: During a 2-year follow-up period, the use of topical cyclosporine A (0.05%) combined with mitomycin C (0.01%) as an adjunctive treatment after surgical excision in cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma was found to prevent tumor recurrence, especially in extensive lesions, when surgical excision cannot ensure a tumor-free margin.
  • [MeSH-major] Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Conjunctival Neoplasms / therapy. Corneal Diseases / therapy. Eye Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclosporine / administration & dosage. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Mitomycin / administration & dosage. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cornea. 2012 Apr;31(4):465 [22314824.001]
  • [CommentIn] Cornea. 2011 Apr;30(4):486; author reply 486-7 [21107255.001]
  • (PMID = 19724215.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


7. Huerva V: [Topical interferon alfa-2b or surgical excision for primary treatment of conjunctiva-cornea intraepithelial neoplasia]. Arch Soc Esp Oftalmol; 2009 Jan;84(1):5-6
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical interferon alfa-2b or surgical excision for primary treatment of conjunctiva-cornea intraepithelial neoplasia].
  • [Transliterated title] Interferón alfa-2b tópico o escisión quirúrgica como tratamiento primario de la neoplasia conjuntival intraepitelial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Cryotherapy. Follow-Up Studies. Humans. Instillation, Drug. Ophthalmic Solutions. Postoperative Complications / prevention & control. Recombinant Proteins. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173133.001).
  • [ISSN] 1989-7286
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


8. Albornoz López R, Fernández García MI, Pérez Rodrigo I: [Topical interferon alpha 2 beta therapy in the management of conjunctival intraepithelial neoplasia]. Farm Hosp; 2007 Nov-Dec;31(6):382-4
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical interferon alpha 2 beta therapy in the management of conjunctival intraepithelial neoplasia].
  • [Transliterated title] Administración tópica de interferón alpha-2b como tratamiento de una neoplasia intraepitelial conjuntival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Farm Hosp. 2009 Nov-Dec;33(6):335-6 [20038393.001]
  • (PMID = 18348671.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


9. Rosner M, Hadar I, Rosen N: Successful treatment with mitomycin C eye drops for conjunctival diffuse intraepithelial neoplasia with sebaceous features. Ophthal Plast Reconstr Surg; 2003 Nov;19(6):477-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with mitomycin C eye drops for conjunctival diffuse intraepithelial neoplasia with sebaceous features.
  • Conjunctival biopsy specimens from the right eye of a 66-year-old woman who had a 10-year history of an irritated and swollen right upper eyelid were diagnosed as diffuse intraepithelial neoplasia with sebaceous features.
  • The treatment consisted of two courses, 2 weeks apart, of 0.02% mitomycin C eye drops.
  • Severe trichiasis that developed after the biopsies was managed surgically.
  • Today, 46 months after completion of mitomycin C treatment, the conjunctiva shows no inflammation, the eyelid is not swollen or irritated, and there is no clinical indication of recurrence.
  • This case report demonstrates that conjunctival diffuse intraepithelial neoplasia of the conjunctiva with sebaceous features can be successfully treated by treatment with mitomycin C drops.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Conjunctival Neoplasms / drug therapy. Conjunctival Neoplasms / pathology. Mitomycin / administration & dosage. Sebaceous Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14625495.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


10. Huerva V, Mateo AJ, Mangues I, Jurjo C: Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia. Cornea; 2006 Dec;25(10):1220-3
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia.
  • PURPOSE: To report a case of extensive conjunctiva-cornea intraepithelial neoplasia (CIN) treated topically with mitomycin C (MMC) and interferon (INF)-alpha2beta without surgical resection.
  • RESULTS: : An 82-year-old woman showed an extensive gelatinous red mass in the bulbar conjunctiva with invasion into the caruncle, inferior fornix, and tarsal conjunctiva and extending for 270 degrees of the corneal surface.
  • A diagnosis of CIN was made by surgical biopsy.
  • A conservative treatment strategy was used with 2 cycles of topical MMC (0.02%), followed by INF-alpha2beta eye drops at a dose of 1 million IU/mL, 4 times a day until tumor disappearance.
  • Total resolution was noted after 75 days of treatment with INF, with no clinical evidence of limbal stem cell deficiency.
  • After 1 year of monitoring, no signs of CIN recurrences were observed.
  • CONCLUSION: MMC (0.02%), followed by INF-alpha2beta (1 million IU/mL) 4 times a day, is an effective treatment against highly extensive CIN, in cases where surgical resection with safety margins is unfeasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Biopsy. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Humans. Interferon-alpha / administration & dosage. Mitomycin / administration & dosage. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172902.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


11. Cartsburg O, Kersten A, Sundmacher R, Nadjari B, Pomjanski N, Böcking A: [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control]. Klin Monbl Augenheilkd; 2001 Jun;218(6):429-34
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control].
  • [Transliterated title] Behandlung von 9 plattenepithelialen Carcinomata in situ der Bindehaut (CIN) mit Mitomycin-C-Augentropfen unter zytologischer und DNA-bildzytometrischer Kontrolle.
  • BACKGROUND: Conjunctival intraepithelial neoplasia (CIN) is a frequent conjunctival tumor.
  • In this study we aimed to evaluate the effectivity of postsurgical chemotherapy of conjunctival squamous cell carcinoma in situ (CIN) with mitomycin C eyedrops.
  • We introduced the otherwise established diagnostic tools of cytology and DNA-image-cytometry to the diagnosis and therapy-monitoring of CIN.
  • PATIENTS AND METHODS: We treated 9 patients with CIN.
  • For diagnosis the results of cytology and cytometry of presurgically obtained brush smears were compared with the histologic evaluation of the excised tissue.
  • After surgery, we administered topical chemotherapy with mitomycin C eye drops 0.02% (MMC).
  • Conjunctival brush smears were again evaluated by cytology and DNA-image-cytometry for postsurgical therapy monitoring.
  • RESULTS: The clinical diagnosis of CIN was fully confirmed by cytology, DNA-image-cytometry and histology respectively in 7 patients.
  • In one patient, the results of the applied diagnostic methods differed in results: Histologic evaluation indicated a moderate dysplasia but DNA-image-cytometry showed significant DNA-aneuploidy unequivocally indicating neoplasia like squamous cell carcinoma.
  • In another patient the preoperatively obtained conjunctival brush smears could not properly analyzed by cytometry but clinical diagnosis was confirmed by histology.
  • MMC-therapy was well tolerated except for a self-limited conjunctivitis.
  • A complete remission of CIN was obtained in 8 of 9 patients (89%) who were free of CIN recurrences during a follow-up period of 27.2 months (11-48).
  • CONCLUSION: Adjuvant topical mitomycin C appears to be effective in the prevention of recurrences of conjunctival CIN after surgical removal.
  • Cytology and DNA-image cytometry are highly sensitive and specific methods for diagnosis and therapy monitoring of conjunctival squamous cell carcinoma in situ (CIN).
  • [MeSH-major] Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. DNA, Neoplasm / analysis. Image Cytometry. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Conjunctiva / pathology. Conjunctiva / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Ophthalmic Solutions. Ploidies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11488009.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


12. Di Pascuale MA, Espana EM, Tseng SC: A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles. Cornea; 2004 Jan;23(1):89-92
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles.
  • PURPOSE: To report a case of conjunctiva-cornea intraepithelial neoplasia (CCIN) treated with topical mitomycin C (MMC) and interferon alfa-2b in cycles.
  • The diagnosis was confirmed by impression cytology and treated in cycles with topical 0.02% MMC for 14 days in the first cycle, 12 days in the second cycle, and 3 days in the third cycle followed by topical interferon alfa-2b 1 x 106 U/mL for 11 days.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / administration & dosage. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Drug Administration Schedule. Female. Humans. Middle Aged. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14701965.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


13. Huerva V, Sánchez MC, Mangues I: Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia. J Ocul Pharmacol Ther; 2007 Apr;23(2):143-5
MedlinePlus Health Information. consumer health - Corneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia.
  • AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure.
  • RESULTS: An 81-year-old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye.
  • Pathognomonic signs of CIN were present.
  • A regimen of topical INF alpha 2-beta 4 times daily was administered.
  • An increase in tumor volume of 25% was observable 15 days after the beginning of therapy.
  • The treatment continued with follow-ups every 15 days.
  • Complete regression of the CIN was observable after 60 days of therapy.
  • CONCLUSIONS: Topical INF alpha 2-beta is a valid choice for the treatment of CIN in patients for whom surgery is not possible.
  • The increase of tumor volume at the beginning of therapy does not require the suspension of treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Eye Neoplasms / drug therapy. Humans. Male. Ophthalmic Solutions. Recombinant Proteins. Remission Induction. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444802.001).
  • [ISSN] 1080-7683
  • [Journal-full-title] Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • [ISO-abbreviation] J Ocul Pharmacol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


14. Ramos-López JF, Martínez-Costa Pérez R, Cisneros Lanuza AL, Francés Muñoz E, Monte Boque E, Muñoz Gómez MC, López-Sánchez EV, Menezo Rozalén JL: [Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%]. Arch Soc Esp Oftalmol; 2004 Aug;79(8):375-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%].
  • [Transliterated title] Tratamiento de las neoplasias conjuntivales intraepiteliales con colirio de mitomicina C al 0,02%
  • PURPOSE: To evaluate the efficacy of topical mitomycin C (MMC) 0.02% in treating conjunctival intraepithelial neoplasia (CIN).
  • METHODS: Three patients with CIN were treated with topical MMC 0.02%.
  • RESULTS: CIN was resolved in all three cases without modifying the normal corneal and conjunctival architecture.
  • CONCLUSIONS: Topical MMC 0.02% four times daily during two weeks is a useful alternative tool for the surgical management of CIN.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Humans. Male. Ophthalmic Solutions. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15306963.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


15. Dogru M, Erturk H, Shimazaki J, Tsubota K, Gul M: Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia. Cornea; 2003 Oct;22(7):627-39
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia.
  • PURPOSE: To evaluate the tear function and ocular surface alterations in patients with primary CIN before and after treatment with topical mitomycin (MMC).
  • PATIENTS AND METHODS: We describe seven patients with unilateral CIN treated with 0.04% topical MMC three times daily until full eradication of the lesion.
  • The patients underwent tear and ocular surface examinations including Cochet-Bonnet corneal sensitivity measurements, tear film break-up time (BUT), Schirmer test, and Rose-Bengal staining before, at the time of resolution of the CIN, and at the final follow-up.
  • Conjunctival impression cytology was performed before treatment and at the last visit.
  • MMC-induced cytologic changes were seen to persist long after cessation of treatment in some patients.
  • CONCLUSION: We found 0.04% topical MMC treatment tid until full eradication to be effective in the management of CIN.
  • The ocular surface disease of CIN was characterized by disturbance of tear film stability, goblet cell loss, and increased squamous metaplasia in all patients.
  • Impression cytology proved useful in attaining the diagnosis of CIN, evaluating the effect of treatment, and showing MMC-related long-term changes on the ocular surface.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Conjunctiva / pathology. Corneal Diseases / drug therapy. Corneal Diseases / pathology. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Mitomycin / administration & dosage. Tears / metabolism

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14508259.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Fluorescent Dyes; 1ZPG1ELY14 / Rose Bengal; 50SG953SK6 / Mitomycin
  •  go-up   go-down


16. Rozenman Y, Frucht-Pery J: Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C. Cornea; 2000 Jan;19(1):1-6
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C.
  • PURPOSE: To evaluate the efficacy and risks of complications of topical mitomycin C (MMC) for small-size conjunctival intraepithelial neoplasia (CIN).
  • METHODS: Eight patients with clinically diagnosed CIN <8 mm were included in the study.
  • Patients received topical drops of MMC, 0.02-0.04%, 4 times daily for 14 days.
  • Retreatment was done when lesions were not eliminated or recurred after the first treatment.
  • After retreatment, the lesions were eradicated in four patients, whereas in one patient, the treatment failed, and the lesion was surgically excised.
  • The complications of MMC use included mild conjunctival hyperemia in two patients and mild allergy in one patient, which resolved after discontinuation of the treatment.
  • CONCLUSION: Application of topical MMC is an effective treatment for most but not all cases of small-size CIN.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Leukoplakia / drug therapy. Leukoplakia / pathology. Male. Middle Aged. Ophthalmic Solutions / administration & dosage. Ophthalmic Solutions / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10631999.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


17. Toledano Fernández N, García Sáenz S, Díaz Valle D, Arteaga Sánchez A, Segura Bedmar M, Lorenzo Giménez S, Cortés Lambea L: [Interferon alfa-2b treatment in selected cases of recurrent conjunctival intraepithelial neoplasia]. Arch Soc Esp Oftalmol; 2003 May;78(5):265-71
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interferon alfa-2b treatment in selected cases of recurrent conjunctival intraepithelial neoplasia].
  • [Transliterated title] Empleo de interferón alfa-2b para el tratamiento de carcinomas conjuntivales intraepiteliales en casos seleccionados.
  • PURPOSE: To study the efficacy of topical and combined topical and subconjunctival interferon alfa 2b (IFN alfa 2b) in the treatment of recurrent conjunctival intraepithelial neoplasia (CIN) in those patients who present resistance or intolerance to topical mitomycin C (MMC) treatment or when it is not indicated.
  • METHODS: Four patients (age range from 52 to 70) with histological confirmation of recurrent CIN were studied prospectively.
  • Two patients were resistant to topical MMC, another one did not tolerate it, and in the last case, this treatment was not indicated due to a stem cell insufficiency associated to a trophic corneal ulcer.
  • Three patients were given just topical interferon (1 million IU/ ml four times a day for three months), while the last one received topical therapy and subconjunctival IFN alfa 2b injections (3 millions IU/ 0.5 ml).
  • RESULTS: Complete regression of the tumour was evident in all cases. sixteen to 24 months after treatment no patient had clinical evidence of recurrence.
  • CONCLUSIONS: IFN alfa 2b is effective as an alternative treatment to topical MMC in selected cases of recurrent CIN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Prospective Studies. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12789630.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


18. Yamamoto N, Ohmura T, Suzuki H, Shirasawa H: Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C. Ophthalmology; 2002 Feb;109(2):249-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C.
  • PURPOSE: To describe the histopathological findings and successful treatment with 5-fluorouracil (5-FU) of a conjunctival intraepithelial neoplasia with limbal stem cell deficiency that was refractive to topical mitomycin-C (MMC).
  • INTERVENTION: A 64-year-old male patient presented with a diffuse conjunctival intraepithelial neoplasia (CIN) that was excised with concurrent keratoepithelioplasty.
  • Despite two courses of MMC, the tumor size did not decrease, and topical 5-FU was started 1 year after MMC therapy began.
  • RESULTS: After 5-FU treatment, the patient was free of the tumor clinically and cytologically, and the corneal surface had cleared.
  • No recurrence was observed during the 30 months after the 5-FU therapy.
  • CONCLUSIONS: Topical 5-FU may be a therapeutic option for the treatment of patients with MMC-resistant CINs.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Fluorouracil / therapeutic use. Mitomycin / therapeutic use
  • [MeSH-minor] Drug Resistance, Neoplasm. Epithelial Cells / transplantation. Humans. Limbus Corneae / cytology. Male. Middle Aged. Neoplasm Recurrence, Local. Stem Cell Transplantation. Transplantation, Autologous. Treatment Outcome

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmology. 2003 Jul;110(7):1289 [12867379.001]
  • [CommentIn] Ophthalmology. 2003 Apr;110(4):625-6; author reply 626 [12689863.001]
  • [CommentIn] Ophthalmology. 2003 Jun;110(6):1262-3; author reply 1263 [12799258.001]
  • (PMID = 11825803.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Boehm MD, Huang AJ: Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology; 2004 Sep;111(9):1755-61
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
  • OBJECTIVE: To evaluate topical interferon alfa 2b (IFNalpha2b) as a single therapeutic agent in the treatment of presumed recurrent corneal and conjunctival intraepithelial neoplasia.
  • PARTICIPANTS: Seven consecutive patients with recurrent corneal and conjunctival intraepithelial neoplasia diagnosed at the University of Minnesota from July 2000 to November 2003 were studied retrospectively.
  • All patients had a history of histologically proven primary corneal and conjunctival intraepithelial neoplasia and were treated by surgery, cryotherapy, radiation, and/or topical mitomycin C before recurrence.
  • INTERVENTION: Patients with a clinical diagnosis of recurrent corneal and conjunctival intraepithelial neoplasia were treated with recombinant topical IFNalpha2b drops (1 million IU/ml) 4 times daily until lesion resolution was noted.
  • MAIN OUTCOME MEASURES: A review of medical records was performed to assess the duration of and response to treatment with topical IFNalpha2b, defined by clinical resolution of corneal and conjunctival intraepithelial neoplasia.
  • RESULTS: The average age of the 7 patients at the initiation of topical IFNalpha2b treatment for presumed recurrent corneal and conjunctival intraepithelial neoplasia was 68.7 years (range, 54-88).
  • Six of 7 patients had successful treatment of recurrent corneal and conjunctival intraepithelial neoplasia lesions with topical IFNalpha2b treatment.
  • The average length of IFNalpha2b treatment to resolution of recurrent corneal and conjunctival intraepithelial neoplasia was 14.5 weeks (range, 5-24).
  • After treatment with topical IFNalpha2b for recurrent corneal and conjunctival intraepithelial neoplasia, 2 patients had another recurrence of corneal and conjunctival intraepithelial neoplasia, noted at 1 year and 2 months, respectively.
  • The average post-treatment follow-up was 11.7 months (range, 8-17) after the resolution of recurrent corneal and conjunctival intraepithelial neoplasia.
  • No side effects of treatment were noted in any patient.
  • CONCLUSIONS: Topical IFNalpha2b as a single therapeutic agent is an effective treatment of presumed recurrent corneal and conjunctival intraepithelial neoplasia.
  • It offers the benefits of topical therapy and avoids the risks of surgical or other interventions-specifically, ocular surface toxicity, cicatricial conjunctival changes, and limbal stem cell deficiency.
  • Larger controlled studies with longer follow-up periods are recommended to confirm the long-term efficacy and safety of this topical treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Ophthalmic Solutions / administration & dosage. Ophthalmic Solutions / therapeutic use. Recombinant Proteins. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmology. 2005 Jul;112(7):1319; author reply 1319 [15993243.001]
  • (PMID = 15350333.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


20. Daniell M, Maini R, Tole D: Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Exp Ophthalmol; 2002 Apr;30(2):94-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia.
  • PURPOSE: To evaluate the efficacy of topical mitomycin C as a treatment of corneal conjunctival intraepithelial neoplasia.
  • METHODS: An open prospective analysis of 20 cases of corneal conjunctival intraepithelial neoplasia with recurrent disease (17 patients) or refusing surgery (three patients) were treated with topical mitomycin C.
  • Treatment was with mitomycin C eye drops, either 0.02% or 0.04%, four times daily for 1 week followed by a week off the cycle then repeated for a second week.
  • The mean time to resolution was 4.5 weeks, the mean number of cycles of treatment was two.
  • CONCLUSIONS: Mitomycin C is effective in inducing regression of corneal conjunctival intraepithelial neoplasia.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Eye Neoplasms / drug therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Ophthalmic Solutions. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11886411.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


21. Pournaras JA, Chamot L, Uffer S, Zografos L: Conjunctival intraepithelial neoplasia in a patient treated with tacrolimus after liver transplantation. Cornea; 2007 Dec;26(10):1261-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival intraepithelial neoplasia in a patient treated with tacrolimus after liver transplantation.
  • PURPOSE: To report a case of conjunctival intraepithelial neoplasia in a patient treated with tacrolimus after liver transplantation for hepatic carcinoma.
  • RESULTS: A 70-year-old man presented with a conjunctival intraepithelial neoplasia that developed on the site of a preexisting pterygium.
  • CONCLUSIONS: We describe a case of intraepithelial conjunctival neoplasia in a patient treated with systemic tacrolimus.
  • [MeSH-major] Carcinoma in Situ / etiology. Conjunctival Neoplasms / etiology. Immunosuppressive Agents / therapeutic use. Liver Transplantation. Tacrolimus / therapeutic use
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Combined Modality Therapy. Humans. Liver Neoplasms / drug therapy. Male. Mitomycin / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043187.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 50SG953SK6 / Mitomycin; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


22. Galor A, Karp CL, Chhabra S, Barnes S, Alfonso EC: Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol; 2010 May;94(5):551-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study.
  • BACKGROUND/AIMS To compare the effectiveness and side-effect profile of two doses of interferon alpha2b (IFNalpha2b) eye-drops (1 million international units (IU)/ml versus 3 million IU/ml) in the treatment of ocular surface squamous neoplasia (OSSN).
  • Twenty-one eyes (19 patients) with conjunctival intraepithelial neoplasia (CIN) were treated with 1 million IU/ml of topical IFN-alpha2b; 12 eyes (nine patients) with CIN were treated with 3 million IU/ml.
  • In patients with CIN, topical therapy eliminated disease in 81% of eyes in the 1 million IU/ml group versus 92%, in the 3 million IU/ml group, p=0.41.
  • The median time to OSSN resolution was 2.8 months in the 1 million IU/ml group and 1.9 months in the 3 million IU/ml group, p=0.55.
  • Neither eye with SCC responded to interferon therapy.
  • Topical therapy was well tolerated.
  • After a median follow-up of 24 months, three recurrences were seen in eyes successfully treated with topical therapy.
  • CONCLUSION In our study, there were no significant differences between the 1 million IU/ml group and the 3 million IU/ml group for the treatment of CIN.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Ophthalmic Solutions. Recombinant Proteins. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493859.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


23. Falco LA, Gruosso PJ, Skolnick K, Bejar L: Topical interferon alpha 2 beta therapy in the management of conjunctival papilloma. Optometry; 2007 Apr;78(4):162-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical interferon alpha 2 beta therapy in the management of conjunctival papilloma.
  • BACKGROUND: This article describes the differential diagnosis of conjunctival papillomas and reviews the treatment options with a focus on the new topical interferon alpha 2 beta therapy.
  • The lesion was diagnosed as a conjunctival papilloma.
  • CONCLUSION: Interferons, in particular interferon alpha-2b (IFN-alpha2beta), have recently been shown to be successful in treating conjunctival papillomas and conjunctival intraepithelial neoplasia (CIN).
  • Previously, treatment was limited to observation for asymptomatic patients.
  • Additional treatment modalities included topical antimetabolite treatment with mitomycin-C and 5-fluorouracil.
  • These treatments, although effective, had significant attendant postsurgical complications and toxic ocular adverse reactions.
  • Interferons represent a new successful treatment modality.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Conjunctival Neoplasms / drug therapy. Interferon-alpha / administration & dosage. Papilloma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400137.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


24. Fuchsluger TA, Hintschich C, Steuhl KP, Meller D: [Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface]. Ophthalmologe; 2006 Feb;103(2):124-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface].
  • [Transliterated title] Adjuvante topische Interferon-alpha-2b-Therapie bei epithelialen Tumoren der Augenoberfläche.
  • PURPOSE: The aim of this study was to evaluate the role of topical interferon-alpha-2b in the adjuvant treatment of corneal and conjunctival tumors.
  • METHOD: In this noncomparative, prospective, interventional case series, five patients with histologically proven conjunctival intraepithelial neoplasia (CIN) after primary excision and amniotic membrane transplantation were treated with interferon (IFN)-alpha-2b eye drops five times daily over a period of 6 weeks (1 million IU/ml Intron A, Schering).
  • RESULTS: In the follow-up period (13.2+/-4,97 months) no clinical evidence of recurrence with only limited treatment side effects such as mild conjunctival hyperemia were recorded after 6 weeks of interferon.
  • In one CIN specimen HPV 16/18 could be detected.
  • CONCLUSIONS: The combination of excisional biopsy and topical interferon-alpha-2b application seems to be an effective and safe treatment for conjunctival intraepithelial neoplasias.
  • Therefore, we prefer this combined treatment to topical interferon-alpha-2b treatment alone, more destructive approaches such as radiation and cryotherapy, or treatment with antimetabolites such as 5-fluorouracil or mitomycin C.
  • [MeSH-major] Conjunctival Neoplasms / drug therapy. Conjunctival Neoplasms / surgery. Epithelium, Corneal / drug effects. Epithelium, Corneal / surgery. Interferon-alpha / administration & dosage. Ophthalmologic Surgical Procedures / methods
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Female. Humans. Male. Middle Aged. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Soc Esp Oftalmol. 2003 May;78(5):265-71 [12789630.001]
  • [Cites] J Interferon Cytokine Res. 2000 Feb;20(2):143-51 [10714549.001]
  • [Cites] Am J Ophthalmol. 1972 Oct;74(4):688-93 [5075137.001]
  • [Cites] Cornea. 2004 Jan;23 (1):89-92 [14701965.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67 [13465720.001]
  • [Cites] Klin Monbl Augenheilkd. 1995 Oct;207(4):239-46 [8587298.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Cornea. 1989;8(1):58-61 [2924586.001]
  • [Cites] Am J Ophthalmol. 2002 Aug;134(2):268-70 [12140037.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Refract Corneal Surg. 1993 Nov-Dec;9(6):443-51 [8117643.001]
  • [Cites] Ophthalmic Surg. 1990 Jan;21(1):27-30 [2325992.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Am J Ophthalmol. 1998 Jan;125(1):118-9 [9437331.001]
  • [Cites] Arch Ophthalmol. 1996 Mar;114(3):257-61 [8600883.001]
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 1987;6(2):78-116 [3301209.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Br J Ophthalmol. 2001 Jul;85(7):785-7 [11423448.001]
  • [Cites] JAMA. 1991 Sep 11;266(10):1375-83 [1715409.001]
  • [Cites] J Interferon Cytokine Res. 1999 Dec;19(12 ):1413-9 [10638710.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1777-9 [15150602.001]
  • [Cites] Ophthalmology. 1994 Feb;101(2):360-4 [8115157.001]
  • [Cites] Surgery. 2001 Nov;130(5):798-808 [11685189.001]
  • [Cites] J Lab Clin Med. 1995 Nov;126(5):474-84 [7595033.001]
  • [Cites] Radiother Oncol. 1990 Mar;17(3):191-7 [2320749.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Yan Ke Xue Bao. 1997 Mar;13(1):35-7 [11189324.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Jpn J Ophthalmol. 2002 Mar-Apr;46(2):215-7 [12062230.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):241-5 [1734085.001]
  • (PMID = 16047150.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b
  •  go-up   go-down


25. Rodríguez-Pérez C, Del Campo Z, Wolley-Dod C, Gris O: [Topical treatment with mitomycin C in considerably raised conjunctival intraepithelial neoplasia]. Arch Soc Esp Oftalmol; 2002 Dec;77(12):685-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical treatment with mitomycin C in considerably raised conjunctival intraepithelial neoplasia].
  • [Transliterated title] Tratamiento tópico con mitomicina C en la neoplasia intraepitelial córneo-conjuntival de gran espesor.
  • CASE REPORT: We present a case of recurrent conjunctival intraepithelial neoplasia, treated previously on two occasions with excisional biopsy.
  • Although the lesion was considerably raised, topical treatment with mitomycin-C 0.04% was applied, achieving the complete regression of the tumor.
  • However, successive treatment cycles can achieve complete regression, even in considerably thick tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Epithelium, Corneal / pathology. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12471516.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


26. Huerva V, Mangues I, Schoenenberger JA: [Interferon alpha 2b eyedrops as treatment of conjunctival intraepithelial neoplasia]. Farm Hosp; 2009 Nov-Dec;33(6):335-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interferon alpha 2b eyedrops as treatment of conjunctival intraepithelial neoplasia].
  • [Transliterated title] Interferón alfa 2b en colirio como tratamiento de la neoplasia conjuntival intraepitelial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Cost-Benefit Analysis. Drug Costs. Humans. Immunologic Factors / administration & dosage. Immunologic Factors / economics. Immunologic Factors / therapeutic use. Multicenter Studies as Topic. Ophthalmic Solutions / economics. Recombinant Proteins. Spain. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Farm Hosp. 2007 Nov-Dec;31(6):382-4 [18348671.001]
  • (PMID = 20038393.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] Comment; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


27. Snyder ME: Conjunctival intraepithelial neoplasia. Ophthalmology; 2003 Jul;110(7):1289
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival intraepithelial neoplasia.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Fluorouracil / therapeutic use
  • [MeSH-minor] Administration, Topical. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Drug Resistance, Neoplasm. Humans. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Neoplasm Recurrence, Local

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ophthalmology. 2002 Feb;109(2):249-52 [11825803.001]
  • (PMID = 12867379.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Esquenazi S, Fry CL, Holley E: Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b. Br J Ophthalmol; 2005 Sep;89(9):1221
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / administration & dosage

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • (PMID = 16113387.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC1772848
  •  go-up   go-down






Advertisement